Bayer, AskBio Presents Baseline Characteristics from Phase 2 Heart Failure Study at ESC

 Phase 2 GenePHIT trial successfully randomized and completed enrollment of one of the largest gene therapy trials conducted in heart failure to date, with more than 170 participants randomized across 64 sites in 12 countries1 / Baseline characteristics demonstrate successful enrollment of a well-characterized population of patients with non-ischemic heart failure with reduced ejection fraction (HFrEF) / Initial efficacy and safety outcomes from GenePHIT are expected in the first half of 2027

https://www.bayer.com/media/en-us/askbio-presents-baseline-characteristics-from-phase-2-heart-failure-gene-therapy-trial-of-umiposgene-parvec-ab-1002-at-european-society-of-cardiology-congress/